Literature DB >> 10844211

Prostatic disorders in the dog.

S D Johnston1, K Kamolpatana, M V Root-Kustritz, G R Johnston.   

Abstract

Common canine prostatic disorders include benign prostatic hypertrophy (BPH), prostatitis, prostatic cysts and prostatic adenocarcinoma. BPH is a spontaneous and age-related disorder of intact male dogs, which occurs in more than 80% male dogs over 5 years of age, and which is associated with clinical signs of sanguinous prostatic fluid, constipation and dysuria. BPH signs respond to castration or to finasteride treatment (0.1-0.5 mg/kg per os once daily), as finasteride inhibits conversion of testosterone to dihydrotestosterone, causing prostatic involution via apoptosis. BPH often occurs concurrently with prostatic infection, abscessation, cysts and neoplasia in the intact dog, and finasteride-induced prostatic involution may be beneficial in treatment of all of these conditions except neoplasia. Two studies suggest that risk of prostatic adenocarcinoma is increased in neutered, compared to intact male dogs. Although canine prostatic neoplasia, unlike human prostatic neoplasia, usually does not respond to androgen deprivation, recent reports of prostatic intraepithelial neoplasia (PIN) in a high percentage of older male dogs, with and without prostatic adenocarcinoma, suggests that PIN may be a precursor to adenocarcinoma in the dog as it is believed to be in man.

Entities:  

Mesh:

Year:  2000        PMID: 10844211     DOI: 10.1016/s0378-4320(00)00101-9

Source DB:  PubMed          Journal:  Anim Reprod Sci        ISSN: 0378-4320            Impact factor:   2.145


  30 in total

1.  Urinary tract disease in dogs: US findings. A mini-pictorial essay.

Authors:  G Robotti; D Lanfranchi
Journal:  J Ultrasound       Date:  2013-05-14

2.  Ultrasonographic Follow-up of the Multistep Protocol for Prostate Cancer Induction in Wistar Rats.

Authors:  MÁrio Ginja; Paula A Oliveira; Ana I Faustino-Rocha; Fernanda Seixas; Rita Ferreira; Jessica Silva; Maria J Pires; Margarida Fardilha
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells.

Authors:  Lisa Y Wu; Jacqueline M Johnson; Jessica K Simmons; Desiree E Mendes; Jonathan J Geruntho; Tiancheng Liu; Wessel P Dirksen; Thomas J Rosol; William C Davis; Clifford E Berkman
Journal:  Prostate       Date:  2014-01-21       Impact factor: 4.104

4.  The evolution of a genetic locus encoding small serine proteinase inhibitors.

Authors:  Adam Clauss; Hans Lilja; Ake Lundwall
Journal:  Biochem Biophys Res Commun       Date:  2005-07-29       Impact factor: 3.575

5.  A retrospective review of canine benign prostatic hyperplasia with and without prostatitis.

Authors:  Hannah Ruetten; Marlyse Wehber; Mary Murphy; Clara Cole; Simran Sandhu; Steven Oakes; Dale Bjorling; Kenneth Waller; Katrina Viviano; Chad Vezina
Journal:  Clin Theriogenology       Date:  2021-12

6.  Frozen-Thawed Sperm Analysis of Benign Prostatic Hyperplasia Dogs Treated With Finasteride.

Authors:  Renato Bueno Flores; Daniel de Souza Ramos Angrimani; Maira Morales Brito; Leticia Lima de Almeida; João Vitor Menezes Lopes; João Diego de Agostini Losano; Camila Infantosi Vannucchi
Journal:  Front Vet Sci       Date:  2022-06-30

7.  Lipids and FA analysis of canine prostate tissue.

Authors:  Nadia M Attar-Bashi; Karyn Orzeszko; Ronald F Slocombe; Andrew J Sinclair
Journal:  Lipids       Date:  2003-06       Impact factor: 1.880

8.  Melphalan, alone or conjugated to an FSH-β peptide, kills murine testicular cells in vitro and transiently suppresses murine spermatogenesis in vivo.

Authors:  John K Amory; SungWoo Hong; Xiaozhong Yu; Charles H Muller; Elaine Faustman; Alex Goldstein
Journal:  Theriogenology       Date:  2014-03-27       Impact factor: 2.740

9.  A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.

Authors:  Simon A Williams; Rosemina F Merchant; Elizabeth Garrett-Mayer; John T Isaacs; J Thomas Buckley; Samuel R Denmeade
Journal:  J Natl Cancer Inst       Date:  2007-03-07       Impact factor: 13.506

10.  Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer.

Authors:  Katharina A Sterenczak; Martin Meier; Silke Glage; Matthias Meyer; Saskia Willenbrock; Patrick Wefstaedt; Martina Dorsch; Jörn Bullerdiek; Hugo Murua Escobar; Hans Hedrich; Ingo Nolte
Journal:  BMC Cancer       Date:  2012-07-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.